Amrutanjan Health Care Ltd
Amrutanjan Health Care Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Amrutanjan Health Care Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY26 Revenue from Operations: Rs. EBITDA for Q3 FY26: Rs.
From Amrutanjan Health Care Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY26 Revenue from Operations: Rs. 141.03 Cr, up 14.90% YoY (Q3 FY25: Rs. 122.75 Cr)
- Gross Sales - OTC (Q3 FY26): Rs. 148.33 Cr, up 12.48% YoY (Q3 FY25: Rs. 131.87 Cr)
- Net Sales - OTC (Q3 FY26): Rs. 137.22 Cr, up 16.43% YoY (Q3 FY25: Rs. 117.86 Cr)
- Net Sales - Comfy (Q3 FY26): Rs. 36.68 Cr, up 22.55% YoY (Q3 FY25: Rs. 29.93 Cr)
- Beverage Gross Sales (Q3 FY26): Rs. 3.64 Cr, down from Rs. 5.54 Cr in Q3 FY25
- Q3 FY26 Profit Before Tax: Rs. 26.36 Cr (minimal growth YoY)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹150 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q3 FY26 results?
Q3 FY26 Revenue from Operations: Rs. EBITDA for Q3 FY26: Rs.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amrutanjan Health Care Ltd planning capital expenditure?
The investor presentation does not mention any capex, capacity expansion, or new plant/project details, amounts, status, or timelines.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.